Carmignac Gestion Purchases New Holdings in Bio-Techne Corp $TECH

Posted by Brian Himes on Sep 8th, 2026

Carmignac Gestion bought a new position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 124,530 shares of the biotechnology company’s stock, valued at approximately $8,798,000. Carmignac Gestion owned 0.08% of Bio-Techne at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. American Capital Management Inc. raised its stake in shares of Bio-Techne by 8.5% in the first quarter. American Capital Management Inc. now owns 1,021,128 shares of the biotechnology company’s stock valued at $53,364,000 after buying an additional 79,979 shares during the period. Nicholas Company Inc. grew its stake in shares of Bio-Techne by 6.5% during the 4th quarter. Nicholas Company Inc. now owns 390,794 shares of the biotechnology company’s stock worth $22,983,000 after acquiring an additional 23,785 shares during the period. S&CO Inc. purchased a new stake in Bio-Techne in the 2nd quarter worth about $5,412,000. Ceredex Value Advisors LLC bought a new stake in Bio-Techne in the 2nd quarter valued at about $8,488,000. Finally, Granite Investment Partners LLC raised its stake in Bio-Techne by 31.3% in the 1st quarter. Granite Investment Partners LLC now owns 137,562 shares of the biotechnology company’s stock valued at $7,189,000 after acquiring an additional 32,754 shares during the period. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Bio-Techne Trading Down 0.2%

Bio-Techne stock traded down $0.12 during mid-day trading on Tuesday, hitting $72.31. The company’s stock had a trading volume of 2,066,670 shares, compared to its average volume of 3,358,520. The business has a 50 day moving average price of $71.87 and a 200-day moving average price of $60.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.55 and a quick ratio of 3.35. Bio-Techne Corp has a 12 month low of $43.19 and a 12 month high of $72.62. The stock has a market cap of $11.34 billion, a price-to-earnings ratio of 62.88, a price-to-earnings-growth ratio of 8.62 and a beta of 1.28.

Bio-Techne (NASDAQ:TECH – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. Bio-Techne had a return on equity of 13.23% and a net margin of 14.97%.The firm had revenue of $321.19 million for the quarter, compared to analysts’ expectations of $314.63 million. During the same period last year, the firm earned $0.53 earnings per share. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. As a group, analysts forecast that Bio-Techne Corp will post 1.76 EPS for the current year.

Bio-Techne Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 4th. Investors of record on Monday, August 24th were given a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 3.6%. The ex-dividend date was Monday, August 24th. This is a positive change from Bio-Techne’s previous quarterly dividend of $0.08. Bio-Techne’s dividend payout ratio is 27.83%.

Analysts Set New Price Targets

Several research analysts recently commented on TECH shares. TD Cowen downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating and raised their price objective for the stock from $65.00 to $73.00 in a report on Monday, June 29th. Zacks Research upgraded shares of Bio-Techne from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. William Blair lowered shares of Bio-Techne from an “outperform” rating to a “market perform” rating in a research report on Thursday, June 25th. Stephens set a $73.00 price objective on Bio-Techne and gave the stock an “equal weight” rating in a report on Friday, June 26th. Finally, Leerink Partners set a $73.00 price objective on Bio-Techne in a report on Thursday, June 25th. Two analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $68.92.

Read Our Latest Stock Analysis on Bio-Techne

Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.